DBV Technologies' Peanut Allergy Patch Trial Advances
Update: 2025-11-12
Description
DBV Technologies shares soared over seven percent in pre-market trading following the completion of the final patient visit in its Phase Three VITESSE clinical trial for a new peanut allergy treatment. The trial, involving 654 participants across 86 locations, is testing the VIASKIN Peanut patch for children aged four to seven. The company remains on track to release main findings later this year, potentially offering a new treatment for this life-threatening condition.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
